Natera announces new data from two studies on Prospera Heart dd-cfDNA test

Natera announced the publication of two major studies, DTRT-2 and Trifecta-Heart, showcasing the ability of the Prospera Heart donor-derived cfDNA test to detect rejection in adult and pediatric heart transplant recipients. These are the second and third peer-reviewed publications evaluating Natera’s technology for use in heart transplantation. The DTRT-2 study, published recently in Pediatric Transplantation, was sponsored by the National Institutes of Health. A total of 487 samples from 160 heart transplant recipients were evaluated, of which 78 were pediatric and 82 were adult patients. The Prospera Heart test demonstrated outstanding performance in detecting rejection, as determined by histopathology from endomyocardial biopsies, with an AUC of 0.82 in adult patients and 0.83 in pediatric patients. The study reported a negative predictive value of 92% for adult patients and 99% for pediatric patients, supporting the intended use of Prospera Heart as a rule-out test to help obviate surveillance biopsy procedures.